132 related articles for article (PubMed ID: 1690349)
1. Proteolytic elimination of decay-accelerating factor (DAF): lytic abnormality coincides with removal of DAF in papain-treated human erythrocytes.
Seya T; Inoue H; Okada M; Matsumoto M; Kitamura H; Kinoshita T; Akedo H
Mol Immunol; 1990 Jan; 27(1):69-78. PubMed ID: 1690349
[TBL] [Abstract][Full Text] [Related]
2. [Immunocytochemical staining of decay-accelerating factor (DAF) on erythrocytes: paroxysmal nocturnal hemoglobinuria (PNH)].
Kobayashi T; Nakazawa M; Sato Y; Tomiyama J; Ninomiya H; Abe T; Terasawa T; Shichishima T; Fujita T
Rinsho Ketsueki; 1992 Feb; 33(2):162-6. PubMed ID: 1378912
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum.
Wilcox LA; Ezzell JL; Bernshaw NJ; Parker CJ
Blood; 1991 Aug; 78(3):820-9. PubMed ID: 1713516
[TBL] [Abstract][Full Text] [Related]
4. Induction of the paroxysmal nocturnal hemoglobinuria phenotype in normal human erythrocytes: effects of 2-aminoethylisothiouronium bromide on membrane proteins that regulate complement.
Ezzell JL; Wilcox LA; Bernshaw NJ; Parker CJ
Blood; 1991 Jun; 77(12):2764-73. PubMed ID: 1710519
[TBL] [Abstract][Full Text] [Related]
5. Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.
Medof ME; Gottlieb A; Kinoshita T; Hall S; Silber R; Nussenzweig V; Rosse WF
J Clin Invest; 1987 Jul; 80(1):165-74. PubMed ID: 2439544
[TBL] [Abstract][Full Text] [Related]
6. Interactions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platelet survival in vivo.
Devine DV; Siegel RS; Rosse WF
J Clin Invest; 1987 Jan; 79(1):131-7. PubMed ID: 2432087
[TBL] [Abstract][Full Text] [Related]
7. Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.
Medof ME; Kinoshita T; Silber R; Nussenzweig V
Proc Natl Acad Sci U S A; 1985 May; 82(9):2980-4. PubMed ID: 2581259
[TBL] [Abstract][Full Text] [Related]
8. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.
Davitz MA; Low MG; Nussenzweig V
J Exp Med; 1986 May; 163(5):1150-61. PubMed ID: 2422313
[TBL] [Abstract][Full Text] [Related]
9. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5430-4. PubMed ID: 6225118
[TBL] [Abstract][Full Text] [Related]
10. The erythrocytes in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis.
Rosse WF; Hoffman S; Campbell M; Borowitz M; Moore JO; Parker CJ
Br J Haematol; 1991 Sep; 79(1):99-107. PubMed ID: 1716964
[TBL] [Abstract][Full Text] [Related]
11. A high m.w. form of decay-accelerating factor (DAF-2) exhibits size abnormalities in paroxysmal nocturnal hemoglobinuria erythrocytes.
Kinoshita T; Rosenfeld SI; Nussenzweig V
J Immunol; 1987 May; 138(9):2994-8. PubMed ID: 2437202
[TBL] [Abstract][Full Text] [Related]
12. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.
Nicholson-Weller A; March JP; Rosenfeld SI; Austen KF
Proc Natl Acad Sci U S A; 1983 Aug; 80(16):5066-70. PubMed ID: 6576376
[TBL] [Abstract][Full Text] [Related]
13. Structural and functional differences between decay-accelerating factor and red cell acetylcholinesterase.
Sugarman J; Devine DV; Rosse WF
Blood; 1986 Sep; 68(3):680-4. PubMed ID: 2427138
[TBL] [Abstract][Full Text] [Related]
14. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.
Kinoshita T; Medof ME; Silber R; Nussenzweig V
J Exp Med; 1985 Jul; 162(1):75-92. PubMed ID: 2409211
[TBL] [Abstract][Full Text] [Related]
15. Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria.
Holguin MH; Wilcox LA; Bernshaw NJ; Rosse WF; Parker CJ
J Clin Invest; 1989 Nov; 84(5):1387-94. PubMed ID: 2478585
[TBL] [Abstract][Full Text] [Related]
16. Heterogenous expression of decay accelerating factor and CD59/membrane attack complex inhibition factor on paroxysmal nocturnal haemoglobinuria (PNH) erythrocytes.
Shichishima T; Terasawa T; Hashimoto C; Ohto H; Uchida T; Maruyama Y
Br J Haematol; 1991 Aug; 78(4):545-50. PubMed ID: 1716957
[TBL] [Abstract][Full Text] [Related]
17. Decay-accelerating factor (DAF) on the blood cell membranes in patients with paroxysmal nocturnal haemoglobinuria (PNH): measurement by enzyme-linked immunosorbent assay (ELISA).
Ninomiya H; Abe T; Shichishima T; Terasawa T; Fujita T
Br J Haematol; 1988 May; 69(1):81-7. PubMed ID: 2454648
[TBL] [Abstract][Full Text] [Related]
18. Decay-accelerating factor is present on paroxysmal nocturnal hemoglobinuria erythroid progenitors and lost during erythropoiesis in vitro.
Moore JG; Frank MM; Müller-Eberhard HJ; Young NS
J Exp Med; 1985 Oct; 162(4):1182-92. PubMed ID: 2413153
[TBL] [Abstract][Full Text] [Related]
19. [Paroxysmal nocturnal hemoglobinuria (PNH) deficiency of major complement-regulatory membrane proteins on erythrocytes].
Ninomiya H; Kobayashi T; Abe T
Rinsho Ketsueki; 1991 Jun; 32(6):612-7. PubMed ID: 1716325
[TBL] [Abstract][Full Text] [Related]
20. Longer in vivo survival of CD59- and decay-accelerating factor-almost normal positive and partly positive erythrocytes in paroxysmal nocturnal hemoglobinuria as compared with negative erythrocytes: a demonstration by differential centrifugation and flow cytometry.
Fujioka S; Yamada T
Blood; 1992 Apr; 79(7):1842-5. PubMed ID: 1373090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
